Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate

Raises Hopes Of Challenging Abecma And Carvykti

Executive Summary

While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.

You may also be interested in...



From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel